GEN News Highlights

Merck Serono Launches IT Services Company

(Page
1
of
1)

Merck Serono, a division of Merck, has formed the fourth company stemming from its Entrepreneur Partnership Program (EPP). The new company, dubbed TQM Insight, is a services company specializing in IT governance, which Merck Serono says is a business-critical need for companies operating in regulated industries such as the pharmaceutical, chemical, and banking sectors. Merck Serono is committing more than €1.8 million (around $2.4 million) in contracts over the next eighteen months and will become TQM Insight’s first client.

“The formation of TQM Insight allows our former employees to capitalize on their experience at Merck Serono, to start a unique and promising business in IT governance,” said Frédéric Wohlwend, Group CIO of Merck. “We strongly believe that TQM Insight’s offering will meet the specific needs of the many companies in the regulated industries based in the Lake Geneva area, and beyond.”

Operational as of January 2013, TQM Insight will initially employ six people from the information service governance unit to be led by Gary Price, formerly the corporate director of IT Governance at Merck Serono.

TQM Insight was set up through Merck Serono’s EPP, an initiative to help employees to start a business focused on activities or compounds from Merck Serono. Since its initiation in May 2012 (not long after Merck Serono closed its Geneva headquarters and moved its functions to Darmstadt, a restructuring that led to the loss of over 500 jobs), the EPP has allowed the creation of three other spin-off and services companies:

Prexton Therapeutics, founded last July and formed around Merck Serono’s R&D portfolio in the field of Parkinson’s disease, with a focus on programs that target the metabotropic glutamate receptors mGluR3 and mGluR4;

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

Be sure to take the GEN Poll

Climate Change

How would you describe the researchers response to the 2°C global temperature target?

They are right on the mark. A 2°C global temperature rise will push us further over the edge. We have to set a lower target.

A 2°C global temperature rise is a reasonable target on which to focus in order to diminish the impact of climate change.

We have already gone beyond the threshold for getting a handle on climate change. So now we just need to learn how to adapt to the inexorable climatic changes with which we will have to deal going forward.

They are right on the mark. A 2°C global temperature rise will push us further over the edge. We have to set a lower target.

41.2%

A 2°C global temperature rise is a reasonable target on which to focus in order to diminish the impact of climate change.

23.5%

We have already gone beyond the threshold for getting a handle on climate change. So now we just need to learn how to adapt to the inexorable climatic changes with which we will have to deal going forward.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.